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SUMMARY 
 
   Purpose: To assess the effect of repeated palliative treatment with high dose rate brachytherapy 
in patients with advanced lung cancer. 
   Material and Methods: Fifty-six patients, 25.3% of a total of 221 patients treated for lung cancer 
with HDR brachytherapy were treated twice, using High Dose Rate Brachytherapy. All patients were 
qualified for repeated brachytherapy due to the recurrence of intrabronchial tumour and acceptable 
remissions after the first treatment. The survival times were compared with selected clinical data. 
Correlations between survival times and subjective breathing difficulties were analyzed separately. 
   Results: The median survival time in the whole group of patients was 8.9 months. The period 
of obtaining a positive clinical response was correlated with a longer survival time (log-rank test, 
p=0.0009, F Cox test, p=0.007). In the multivariate analysis other statistically important prognostic 
factors were also included: the clinical stage of the primary tumour (F Cox test, p=0.04), and the 
interval between the first and second treatment (F Cox, p=0.004). None of the analyzed factors (dys-
pnoea, cough, haemoptysis and pain) had any influence on survival. 
   Conclusion: Repeated HDR brachytherapy in advanced lung cancer was an efficient method that 
in many patients led to regression of symptoms and improvement in life quality. 
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INTRODUCTION 
 
   Palliative brachytherapy can be applied 
in three situations: (1) it is often used for 
palliative purposes in patients with a recu-
rrent endobronchial disease after prior ex-
ternal irradiation to relieve life-threatening 
symptoms, such as haemoptysis and air-
way obstruction with an associated atelec-
tasis and pneumonia, (2) it is less fre-
quently used in combination with external 
beam irradiation to deliver an additional 
"boost" with curative intent to the primary 
endobronchial lesion, and (3) it is often 
used in newly diagnosed patients, i.e. 
those without  previous or additional 
external beam irradiation [1-5]. 
   Because of uncontrolled local or recur-
rent disease, patients may display signify-
cant cough, dyspnoea and haemoptysis.  
In many patients, these symptoms are 
primarily attributable to endobronchial 
obstruction. Efforts to relieve this obstruc-
tive process are worthwhile because, as 
an effect, patients may experience a signi-
ficantly improved quality of life. However, 
many of these patients have a poor per-
formance status and/or have a record of 
receiving multiple other therapies. As a re-
sult, treatment options are often limited [6-
10]. 
   Due to the location of the lesion inside 
the bronchial tube, the degree of clinical 
advancement, and the patient’s general 
condition, in some patients brachytherapy 
is a treatment of choice, which, when 
carried out on an out-patient basis, takes 
a short time and leads to a small number 
of early complications [11-12]. 
   In some cases, this treatment can be 
repeated when dyspnoea returns. This ari-
ses from the fact that local irradiation in-
volves relative good adjacent health tissue 
sparing.  Another reason is that often other 
modes of treatment are not available. 
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   The present work reports results of re-
peated palliative treatment using high 
dose rate brachytherapy in patients with 
advanced lung cancer. Influence of cho-
sen clinical data and grade of breathing 
difficulties on survival is analyzed. 
 
MATERIAL AND METHODS 
 
1. Material 
 
   Fifty-six patients, that is 25.3% out of 
221 patients treated for lung cancer with 
HDR brachytherapy between May 1999 
and May 2001 at the Great Poland Cancer 
Center, were treated twice using High 
Dose Rate Brachytherapy. All patients 
were individually qualified for each irra-
diation because of the recurrence of intra-
bronchial tumour and acceptable remi-
ssion after the first treatment. 
   The median interval between both treat-
ments was 6 months. The group of pa-
tients included 48 men and 8 women, their 
age ranging from 39 to 81 years (median 
61.0 years). In all patients bronchoscopy 
and computed tomography (CT) were per-
formed for histological diagnosis and for 
the evaluation of the tumour extent. 
   Thirty-six patients had squamous cell 
carcinoma (SCC), eight had adenocarci-
noma (ACC), four had anaplastic carci-
noma, four had solid cancer, and four had 
unclassified carcinoma. 
   In 10 (17.9%) cases, the tumour was 
localized in the trachea infiltrating the main 
bronchus, in 29 (51.8%) cases in the main 
bronchus, and in 17 (30.4%) cases in the 
lobular bronchus. 
   Summarized clinical data on the patients 
are presented in Table 1. 
   Most patients were in a bad performance 
status (according to the Zubrod score): 
12 (21.4%), 28 (50%) and 16 (28.6%) had 
the Zubrod 1, Zubrod 2 and Zubrod 3 sta-
tus, respectively. The leading clinical sym-
ptoms were dyspnoea, cough, haemopty-
sis and pain. Some patients showed more 
than one symptom at diagnosis (Table 2). 
The symptoms were arranged according 
to the Speiser and Spratling scale for asse-
ssing the palliative response in endobron-
chial brachytherapy [13]. 
 
Table 1. Clinical characteristic of patients. 
 
Clinical data Number of patients 
1/ Age: 
< 61 
> 61 
2/ Sex: 
Male: 
Female: 
3/ Clinical stage (primary lesion): 
T3 N1 
T3 N2 
T4 N0-X 
T1-4 N0-X M1 
4/ Location of tumour: 
Trachea infiltrating bronchus 
Main bronchus 
Lobular bronchus 
5/ Histopathological type: 
Squamous cell carcinoma 
Adenocarcinoma 
Carcinoma solidum 
Anaplastic carcinoma 
Unclassified carcinoma 
6/ Obturation grade: 
< 50% 
> 50% 
almost total 
total 
7/ Interval length between the first and second treatment: 
< 6 months 
> 6 months 
8/ Remission after 4 weeks: 
CR 
PR 
NR 
Average: 61,0 
29 (51,8%) 
27 (48,2%) 
 
48 (85,7%) 
8 (14,3%) 
 
6 (10,7%) 
8 (14,3%) 
31 (55,3%) 
11 (19,6%) 
 
10 (17,9%) 
29 (51.8%) 
17 (30,4%) 
 
36 (64,3%) 
8 (14,3%) 
4 (7,1%) 
4 (7,1%) 
4 (7,1%) 
 
4 (7,1%) 
10 (17,9%) 
25 (44,6%) 
17 (30,4%) 
 
46 (82,1%) 
10 (17,9%) 
 
4 (7,1%) 
42 (75%) 
10 (17,9%) 
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Table 2. Performance status of patients in time of repeated brachytherapy 
 
Performance status data Number of patients 
1/ Zubrod (WHO) score: 
1 
2 
3 
2/ Dyspnoea: 
0 
1 
2 
3 
4 
3/ Cough: 
0 
1 
2 
3 
4/ Hemaptoe: 
0 
1 
2 
3 
5/ Pain: 
0 
1 
2 
3 
 
12 (21,4%) 
28 (50%) 
16 (28,6%) 
 
2 (3,6%) 
12 (21,4%) 
27 (48,2%) 
13 (23,2%) 
2 (3,6%) 
 
3 (5,3%) 
24 (42,8%) 
27 (48,2%) 
2 (3,6%) 
 
8 (14,3%) 
25 (44,6%) 
18 (32,1%) 
5 (8,9%) 
 
13 (23,2%) 
29 (51,8%) 
13 (23,2%) 
1 (1,8%) 
 
Speiser and Spratling Scale for assessing palliative response in endobronchial brachytherapy [13] 
 
2. Treatment 
 
   At the first treatment all 56 patients re-
ceived a total dose of 22.5 Gy in 3 frac-
tions every week. The second treatment 
in all cases involved a single 10 Gy frac-
tion. 
   Endobronchial irradiation was performed 
after local anaesthesia and sedation with 
midazolam. The applicator tube, loaded 
with a ribbon of dummy seeds, was posi-
tionned under endoscopical and fluorosco-
pical control. The target volume was defi-
ned by prior endoscopical and radiological 
findings. A high-dose-rate afterloading ma-
chine (Gammamed 12i, Isotopentechnik 
Dr. Sauerwein, Haan, Germany) with an 
l92 Iridium stepping source and a nominal 
activity of 370 GBq (10 Ci) was used. 
To calculate dose distributions an ABACUS 
computer programme was employed. 
The dose was prescribed at a 10-mm 
distance to the surface of the source. 
The target volume included the residual 
tumour visualized by bronchoscopy or pro-
ven by biopsy plus 2 cm safety margins 
in cranial and caudal direction. In all pa-
tients, the applications were performed 
with a 1.8 mm bronchus applicator (length 
1300 mm) inserted endoscopically before 
treatment. 
3. Methods 
 
   Clinical and endobronchial observations 
were based on the rating of local remi-
ssion and regression of difficulties with 
breathing, cough and haemoptysis. Remi-
ssion of the tumour was assessed in the 
first month after brachytherapy, then in the 
third, sixth and twelfth month. 
   Partial remission (PR) was defined as 
a 50% reduction in the tumour volume, 
measured by CT and bronchoscopy. 
Complete remission (CR) and progressive 
disease (PD) were defined as lack of evi-
dence of local tumour or further tumour 
growth exceeding 25%. No remission (NR) 
was defined as no change in tumour size 
or tumor growth of less then 25%. 
   The results were compared with some 
selected clinical factors such as age, sex, 
histopathology, clinical stage, the Zubrod 
score, remission of the tumour assessed 
after the 1th month, location of the tumour, 
grade of obturation, the interval between 
1st and 2nd treatment, and the administered 
dose. 
 
4. Statistical evaluation 
 
   The survival time was defined as the ti-
me from the beginning of the second bra-
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chytherapy to the death of the patient, 
or to the end of the twelfth month of obser-
vation. Univariate and multivariate catego-
rized analysis were made using the Ka-
plan – Meier method and log-rank, F Cox 
tests were performed for the overall sur-
vival. In none of the categorized data such 
as age and interval between 1st and 2nd 
treatment Cox’s regression model was 
used. 
 
RESULTS 
 
   The median survival time (Kaplan-Meier) 
in the whole group of patients was 
8.9 months (figure 1). After the first month 
from the end of the second treatment 
in 46/56 (82.1%) patients subjective and 
clinical (CR+PR) improvement (regression 
of all symptoms) was observed (Table 1). 
   A positive response was correlated with 
longer survival time. Patients with endo-
scopically controlled complete or partial 
remission had significantly longer survival 
times in comparison with patients whose 
tumour size remained unchanged (figure 
2, log-rank test, p=0.0009, F Cox test, 
p=0.007). After 3 months, CR in 2/56 
(3,6%) cases, PR in 37/56 (66,1%) cases, 
NR in 7/56 (12,5%) cases were noted, 
and in 10 cases (17,9%) progression was 
observed. After 6 months, CR in 2/56 
(3,6%) cases, PR in 19/56 (33,9%) cases, 
progression/recurrence in 23/56 (41,1%) 
cases  were noted. 
   Twelve (21,4%) patients died in the first 
6 months of observation. During one year 
of observation 47 patients (83.9%) died, 
in 3 alive patients (5.4%) improvement 
of dyspnoea was noted, and in 6 patients 
(10.7%) recurrence and progression of the 
disease was observed. Most frequent 
cause of death were local recurrence 
alone or with dissemination. 
   Univariate categorized analysis revealed 
no differences in survival times in relation 
to sex and age (log-rank test, p=0.37 for 
age, p= 0.6 for sex). Patients’ age was 
classified in two groups: equal or lower 
than the median and that higher than the 
median. Absence of statistical significance 
with age was confirmed by all the catego-
rized factors analyzed (p=0.09). 
   The influence of the clinical stage of the 
primary tumour on survival was analyzed. 
Patients were divided into three groups 
(Table 1). Less advanced stage at the first 
treatment corresponded to longer survival. 
In the multivariate analysis we found a si-
gnificant difference in the survival times 
between groups (figure 3, F Cox test, 
p=0.04). 
   Survival was analyzed according to the 
Zubrod (WHO) score. Statistical analysis 
revealed a significant difference between 
patients with the Zubrod score of 1 (12, 
21.40%), 2 (28, 50%) and 3 (16, 28.6%), 
respectively (figure 4, log-rank test, 
p=0.005). 
   The influence of tumour location on sur-
vival was analyzed. For statistical analysis 
our patients were divided into three 
groups: those with trachea infiltrating bron-
chus (10, 17.9%), with the main bronchus 
(27, 48.2%) and with the lobular bronchus 
(17, 30.4%). In the univariate analysis tu-
mour location had significant influence on 
survival (figure 5, log-rank test, p=0.04). 
   The influence of the interval between 
the first and second treatment on survival 
times was analyzed. Longer interval (equal 
or more than 6 months) led to longer 
survival compared (figure 6, log-rank test, 
p=0.001, F Cox p=0.004). 
   The influence of the obturation grade on 
survival was not observed (log-rank test, 
p=0.8), neither have we found statistically 
significant correlations between survival 
and fractionation schema used in the first 
brachytherapy treatment (3 x 7.5Gy or 1 x 
10 Gy) (log-rank test, p=0.3) and histopa-
thology (log-rank test, p=0.3). 
   Correlations between survival times and 
subjective breathing difficulties were ana-
lyzed separately. None of the analyzed 
factors (Table 2) - dyspnoea, cough, hae-
moptysis and pain – divided into groups 
according to Speiser and Spratling [13]) - 
had any influence on survival (log-rank 
test, respectively, p=0.18, p=0.06, p=0.3, 
p=0.25). 
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Fig. 1. Surviving for all patients (Kaplan Meier). 
 
 
 
 
 
Fig. 2. Influence of local response assessed in 1st month after brachytherapy on survival (log rank p=0,008, F Cox p=0,007). 
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Fig. 3. Influence of clinical stage on survival (F Cox p=0,04). 
 
 
 
 
 
Fig. 4. Survival according to Zubrod (WHO) score (log rank p=0,005). 
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Fig. 5. Influence of tumour location on survival (log rank p=0,04) 
 
 
 
 
 
Fig. 6. Influence of interval length between treatments on survival (log rank p=0,001, F Cox p=0,004). 
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COMPLICATIONS 
 
   There were no complications during 
bronchoscopy and catheter positioning. 
In monthly repeated bronchoscopy we 
could observe gradual improvement in all 
cases with necrosis. Forty-two (75.0%) 
patients presented with early superficial 
mucosal necrosis (assessed in 1st month 
after brachytherapy, SOMA Evaluation – 
grade 1 and 2) were successfully treated 
pharmacologically. Higher temperature 
and exhausting cough were most frequent 
complications. In 6 cases (10,7%) during 
12 months of follow-up we found  broncho 
- esophageal fistula. No early life threat-
ening complications were observed. 
 
DISCUSSION 
 
   An airway obstruction, secondary to ex-
tensive primary or recurrent intrathoracic 
cancer, occurs frequently and creates 
devastating effects on many patients. 
There are many therapeutic modalities 
available that can be used to relieve this 
obstruction, including laser therapy, exter-
nal beam irradiation, chemotherapy, and 
endobronchial brachytherapy [1,4,14-16]. 
   External beam irradiation, although effe-
ctive, may not be possible in many pa-
tients (primarily in those who had received 
prior treatment) because of the proximity 
of dose limiting structures adjacent to the 
tracheobronchial tree (eg. esophagus, spi-
nal cord). In addition, external beam irra-
diation can have significant side effects 
(i.e. dysphagia) and result in unnecessary 
normal tissue damage. 
   Endobronchial brachytherapy provides 
prompt relief of symptoms in patients with 
recurrent intraluminal airway tumours 
[10,16-18]. 
   There are only few papers reporting re-
sults of repeated irradiation after previous 
external beam therapy or brachytherapy. 
Authors have not found reports concerning 
repeated second HDR brachytherapy 
in advanced lung cancer. 
   In one of the recently published papers 
authors [17] reviewed a series of patients 
with local recurrence of lung cancer to 
evaluate the efficacy and safety of external 
beam reirradiation. Reirradiation was per-
formed in 18 patients with the aim of 
achieving a cure or prolongation of survi-
val (radical treatment), while 16 patients 
were treated for improvement of their sym-
ptoms (symptomatic treatment). The ove-
rall survival rate after reirradiation was 
43% at 1 year and 27% at 2 years, with 
a median survival time of 8 months. 
The median survival time after radical 
treatment was 15 months, with a range 
of 3 to 58 months, whereas that after 
symptomatic treatment was 3 months, with 
a range of 1 to 14 months. 
   Delclos et al. [2] evaluated toxicity and 
efficacy of endobronchial brachytherapy 
for recurrent endobronchial lesions in 81 
patients. For most patients, a dose of 
30 Gy in two fractions over two weeks was 
delivered. In sixty-eight patients (84%) 
some response was obtained. The median 
duration of response was 4.5 months. 
Patients with excellent response (32%) 
had a significantly better survival (13.3 
months) compared with that of other pa-
tients (5.4 months) (p=0.01). There were 
only two fatal complications, which were 
due to fistula and tracheal malacia. 
   Taulelle et al. [5] analyzed a group of 
189 patients treated with HDR brachy-
therapy. Most patients (69.3%) had rece-
ived prior treatment and revealed sym-
ptomatic bronchial obstruction due to ei-
ther recurrent or residual endobronchial 
disease. Treatment was performed weekly 
and consisted of three to four 8 to 10 Gy 
fractions. Complete endoscopic response 
was observed in 54% of cases. The me-
dian survival was 7 months for the entire 
group. Using a univariate analysis, no fac-
tor was found to be predictive of late pul-
monary toxicity. The study confirmed 
the usefulness of endobronchial brachy-
therapy in alleviating symptoms caused by 
endobronchial recurrence of bronchogenic 
carcinoma. 
Speiser and Spratling [13] observed 
symptomatic response rates of 85-99% 
in 342 patients receiving a range of HDR 
protocols divided into two groups – one 
treated with a fraction of 10 Gy and the 
other treated with 7 Gy. Response rates 
were similar in both groups. The authors 
have observed a significant decrease in 
bronchoscopic response in patients trea-
ted with palliative brachytherapy for rela-
pse following external beam radiation as 
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compared with those who had not rece-
ived previous external beam radiation, i.e., 
70% and 84%, respectively. 
   Micke et al. [19] reported the results of 
HDR brachytherapy in 16 patients with 
recurrent lung cancer after external beam 
radiation (50 – 60 Gy). The recurrences 
were treated using 2 to 4 applications of 5 
to 6 Gy each. The median period of re-
mission was 4 months, whereas the me-
dian survival time was 9 months. 56% 
of patients achieved partial or complete 
remission, 81.3% achieved improvement 
in dyspnoea. 
   Gustafson et al [20] noted significant 
clinical improvement in 74% of 38 sym-
ptomatic patients with recurrent lung can-
cer treated by 21 Gy given in 3 HDR 
applications. Twelve patients received 
prior external beam irradiation (median 
dose of 58 Gy). Twenty-five patients (69%) 
had a partial or complete response on 
radiographic examination. In patients wit-
hout prior irradiation there was a tendency 
for a higher percentage of clinical res-
ponse. None of the factors used predicted 
an increased risk of complications. 
   Ornadel et al. [21] have undertaken 
a prospective analysis of symptom res-
ponse, duration response and prognostic 
factors in 117 patients treated with brachy-
therapy. A single dose of 15 Gy was given. 
Ninety-two patients had received previous 
external beam radiotherapy. The external 
beam radiotherapy dose ranged from 
20 Gy in 5 patients to 60 Gy in 30 frac-
tions. The median survival time was 12 
months. There was no correlation between 
the total dose of the prior external beam 
therapy and the survival rate or rate of fa-
tal haemoptysis. 
   In the Bedwinek et al. [22] series, 38 pa-
tients were treated with high dose rate 
endobronchial brachytherapy to palliate 
symptoms caused by endobronchial recur-
rence of previously irradiated (> 5000 cGy) 
lung cancer. Twenty-nine (76%) patients 
had symptomatic improvement in respon-
se to a dose of 18 Gy, given in 3 HDR 
sessions weekly. The median duration 
of symptoms relief was 7.5 months. 
Bronchoscopy carried out 3 months after 
brachytherapy revealed that 41% had 
complete regression and another 41% had 
partial regression. Location of the recur-
rence was the most important predictor 
of pulmonary haemorrhage. 
   Kelly et al [18] investigated the outcome 
of 175 lung cancer patients who under-
went HDR brachytherapy for recurrent or 
metastatic tumours. The median actuarial 
survival for the entire group was 6 months 
from the time of the first HDR brachy-
therapy treatment session, 160 patients 
having previously received external beam 
radiation. Of the 175 patients (66%) who 
showed symptomatic improvement, 32% 
were much improved and 34% were sli-
ghtly improved. Patients showing impro-
vement survived for significantly longer 
than those who showed no change or 
worsening of symptoms (7 vs. 4 months, 
p = 0.0032). Complications occurred in 19 
patients (11% crude rate) with an actuarial 
complication rate of 13% at 1 year from 
the time of the first brachytherapy treat-
ment session. The authors concluded that 
HDR brachytherapy effectively palliates 
most patients’ symptoms caused by endo-
bronchial lesions. This relief correlates si-
gnificantly with an overall survival benefit. 
   A number of studies concerning brachy-
therapy for recurrence after external irra-
diation reported the incidence of these 
fatal complications as ranging from 0 to 
50% [21-27]. 
   One of the published randomized stu-
dies [28] was conducted to investigate 
whether endobronchial brachytherapy 
(EBB) is a risk factor for massive haemo-
ptysis in 938 patients primarily treated by 
a combination of EBB and external irradia-
tion (XRT) for lung cancer. One hundred-
one out of 938 patients (10.8%) died from 
massive haemoptysis. The incidence of 
massive haemoptysis depended signify-
cantly on the fraction size of brachythe-
rapy. The authors concluded that a com-
bination of EBB and XRT as primary treat-
ment for NSCLC did not lead to a higher 
risk of massive haemoptysis as compared 
with XRT alone, when fraction sizes for 
EBB of 7.5 or 10 Gy are used. 
   Our results of treatment confirmed 
the usefulness of repeated brachytherapy 
in the treatment of advanced recurrent 
lung cancer. Periodical regression of dys-
pnoea was found in all patients. In some 
cases, the improvement occurred within 
a few hours after the termination of bra-
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chytherapy. Regression of dyspnoea was 
associated with less intense cough, sma-
ller haemoptysis, lower pain in the media-
stinum or fewer symptoms of atelectasis. 
   Complete remission observed in the first 
month after treatment was the most im-
portant prognostic factor indicating pro-
longed survival. There were other signify-
cant correlations found in the multivariate 
analysis: between survival and clinical 
stage of primary tumour and between 
survival and interval length between first 
and second treatment. In the univariate 
analysis additional correlations were noted 
between the survival and the Zubrod score 
and between survival and location of the 
tumour. Tolerance of repeated treatment 
was good in most cases, in 42 patients 
(75,0%) a superficial intermittent mucosal 
necrosis, in 6 cases  broncho-esophageal 
fistulae were observed. Mucosal necrosis 
was successfully treated pharmacology-
cally during observation. A number of 
complications were not different from 
the results obtained by other authors. 
No early life threatening complications 
were observed.. 
   It seems that complete local remission 
after brachytherapy is more important 
in patients with recurrent lung cancer than 
other clinical factors such as age, sex, 
histopathology, tumour obturation or me-
thod of fractionation used in prior irra-
diation. The prognostic role of clinical 
stage is emphasized by many authors, 
the same is true for the length of the 
interval between both treatments. The high 
summary local dose (especially in bron-
chial wall) did not lead to any increase 
in complications. 
 
CONCLUSIONS 
 
1. Repeated HDR brachytherapy in ad-
vanced lung cancer was an efficient 
method that in many patients caused 
regression of the symptoms and led to the 
improvement of life quality. 
2. The survival time was correlated with 
(1) a positive response (complete or pa-
rtial) at the first follow-up after the end 
of the treatment, (2) a clinical stage of the 
primary tumour and (3) the length of the 
interval between the first and second 
treatment. 
3. High total doses influenced the frequen-
cy rate of temporary early complications, 
in the majority of patients, however super-
ficial mucosal necrosis was observed. 
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